BACKGROUND: Impairment of coronary microvascular perfusion is common among patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Cardiovascular magnetic resonance imaging (CMR) can identify microvascular obstruction (MO) following reperfusion of STEMI. We hypothesized that myocardial perfusion, as assessed by the Thrombolysis in Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG), would be associated with a CMR metric of MO in this population. METHODS: Twenty-one STEMI patients who underwent successful primary PCI were evaluated. Contrast-enhanced CMR was performed within 7 days of presentation and repeated at three months. TIMI Flow Grade (TFG), corrected TIMI Frame Count (cTFC), TMPG, MO, infarct size, and left ventricular ejection fraction (EF) were assessed. RESULTS: The median peak creatine phosphokinase (CPK) was 1,775 IU/l (interquartile range 838-3,321). TFG 3 was present following PCI in 19 (90%) patients. CMR evidence of MO was present in 52% following PCI. Abnormal post-PCI TMPG (0/1/2) was present in 48% of subjects and was associated with MO on CMR (90% MO with TMPG 0/1/2 vs. 18% MO with TMPG 3, P < 0.01). Abnormal post-PCI TMPG was also associated with a greater peak CK (median 3,623 IU/l vs. 838 IU/l, P < 0.001) and greater relative infarct size (17.3% vs. 5.2%, P < 0.01). CONCLUSION: Among STEMI patients undergoing primary PCI, post-PCI TMPG correlates with CMR measures of MO and infarct size. The combined use of both metrics in a comprehensive assessment of microvascular integrity and infarct size following STEMI may aid in the evaluation of future therapeutic strategies.
BACKGROUND: Impairment of coronary microvascular perfusion is common among patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Cardiovascular magnetic resonance imaging (CMR) can identify microvascular obstruction (MO) following reperfusion of STEMI. We hypothesized that myocardial perfusion, as assessed by the Thrombolysis in Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG), would be associated with a CMR metric of MO in this population. METHODS: Twenty-one STEMI patients who underwent successful primary PCI were evaluated. Contrast-enhanced CMR was performed within 7 days of presentation and repeated at three months. TIMI Flow Grade (TFG), corrected TIMI Frame Count (cTFC), TMPG, MO, infarct size, and left ventricular ejection fraction (EF) were assessed. RESULTS: The median peak creatine phosphokinase (CPK) was 1,775 IU/l (interquartile range 838-3,321). TFG 3 was present following PCI in 19 (90%) patients. CMR evidence of MO was present in 52% following PCI. Abnormal post-PCI TMPG (0/1/2) was present in 48% of subjects and was associated with MO on CMR (90% MO with TMPG 0/1/2 vs. 18% MO with TMPG 3, P < 0.01). Abnormal post-PCI TMPG was also associated with a greater peak CK (median 3,623 IU/l vs. 838 IU/l, P < 0.001) and greater relative infarct size (17.3% vs. 5.2%, P < 0.01). CONCLUSION: Among STEMI patients undergoing primary PCI, post-PCI TMPG correlates with CMR measures of MO and infarct size. The combined use of both metrics in a comprehensive assessment of microvascular integrity and infarct size following STEMI may aid in the evaluation of future therapeutic strategies.
Authors: Timo Baks; Filippo Cademartiri; Amber D Moelker; Annick C Weustink; Robert-Jan van Geuns; Nico R Mollet; Gabriel P Krestin; Dirk J Duncker; Pim J de Feyter Journal: J Am Coll Cardiol Date: 2006-06-09 Impact factor: 24.094
Authors: Italo Porto; Joseph B Selvanayagam; William J Van Gaal; Francesco Prati; Adrian Cheng; Keith Channon; Stefan Neubauer; Adrian P Banning Journal: Circulation Date: 2006-08-07 Impact factor: 29.690
Authors: Krzysztof Zmudka; Jarosław Zalewski; Tadeusz Przewłocki; Wojciech Zajdel; Piotr Czunko; Monika Durak; Cafer Zorkun; Piotr Podolec; Wiesława Tracz Journal: Kardiol Pol Date: 2004-10 Impact factor: 3.108
Authors: S G Ellis; E R da Silva; G Heyndrickx; J D Talley; C Cernigliaro; G Steg; C Spaulding; M Nobuyoshi; R Erbel; C Vassanelli Journal: Circulation Date: 1994-11 Impact factor: 29.690
Authors: E M Antman; H A Cooper; C M Gibson; J A de Lemos; C H McCabe; R P Giugliano; P Coussement; S Murphy; J Scherer; K Anderson; F Van de Werf; E Braunwald Journal: Eur Heart J Date: 2002-06 Impact factor: 29.983
Authors: Shaheeda Ahmed; C Michael Gibson; Christopher P Cannon; Sabina A Murphy; Marc S Sabatine Journal: J Thromb Thrombolysis Date: 2011-05 Impact factor: 2.300
Authors: Anne Bethke; Limalanathan Shanmuganathan; Christian Shetelig; David Swanson; Geir Øystein Andersen; Jan Eritsland; Nils Einar Kløw; Pavel Hoffmann Journal: PLoS One Date: 2018-11-09 Impact factor: 3.240
Authors: Alexander R Payne; Colin Berry; Orla Doolin; Margaret McEntegart; Mark C Petrie; M Mitchell Lindsay; Stuart Hood; David Carrick; Niko Tzemos; Peter Weale; Christie McComb; John Foster; Ian Ford; Keith G Oldroyd Journal: J Am Heart Assoc Date: 2012-08-24 Impact factor: 5.501